Clinical Trials

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06834074 2026-05-14

NVL-655-EAP

Temporarily not available

Carcinoma, Non-Small-Cell Lung

NCT04830202 2026-05-13

Expanded Access to Telisotuzumab Vedotin

Carcinoma, Non-Small-Cell Lung

NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

CNS

Neurofibromatoses, Neurofibroma, Plexiform

NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Sarcoma

Desmoid Tumors

NCT06915766 2026-05-08

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT06948955 2026-05-08

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT07573215 2026-05-07

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Pancreatic Neoplasms

NCT05572970 2026-05-06

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Tumor-Agnostic

Neoplasms

NCT07535359 2026-05-06

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

Small Cell Lung Carcinoma

NCT06761976 2026-05-05

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Tumor-Agnostic

Neoplasms

NCT07536815 2026-04-27

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

Breast

Triple Negative Breast Neoplasms

NCT05593185 2026-04-24

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Melanoma

NCT04085653 2026-04-14

Managed Access Programs for BYL719, Alpelisib

Breast

Breast Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Breast

Breast Neoplasms

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05776134 2026-04-08

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

LymphoidOther hematologic neoplasm

Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT07502716 2026-03-31

Compassionate Use of Ubamatamab

Sarcoma

NCT07497984 2026-03-27

ITM11 Expanded Access Program

CNS

Meningioma

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04507503 2026-03-10

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing

Cholangiocarcinoma

NCT06404034 2026-03-04

Expanded Access to Gallium Maltolate (GaM)

CNS

Glioblastoma

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT06799221 2026-02-27

Expanded Access Program for OOS Obe-cel

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07399015 2026-02-18

Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC

Anophthalmia with pulmonary hypoplasia, Pancreatic Neoplasms

NCT06797362 2026-02-17

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Carcinoma, Non-Small-Cell Lung

NCT05346835 2026-02-13

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Plasma cell

Multiple Myeloma

NCT06439966 2026-02-12

Expanded Access to ABBV-787

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06617572 2026-02-09

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

NCT05982873 2026-02-06

Expanded Access to Telisotuzumab Adizutecan

Other solid neoplasm

Solid Tumors

NCT03123029 2026-01-30

Expanded Access to Venetoclax

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06195514 2026-01-30

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Neoplasms

NCT07310277 2026-01-29

Expanded Access to ABBV-706

Small Cell Lung Carcinoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03756311 2026-01-23

Expanded Access to NanoPac

GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

NCT04060628 2026-01-23

Expanded Access to NanoDoce

Temporarily not available

Urogenital Neoplasms

NCT07346105 2026-01-16

Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06063746 2026-01-08

Compassionate Use of Vidutolimod

Melanoma

NCT06910137 2026-01-08

An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Temporarily not available

Anus Neoplasms, Carcinoma, Squamous Cell

NCT07319910 2026-01-06

PANOVA-3CA

Locally Advanced Pancreatic Adenocarcinoma

NCT06841874 2025-12-24

Tale EAP

Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05619367 2025-12-23

A Compassionate Use (CU) Program of Odronextamab

Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04489433 2025-12-18

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Melanoma

NCT06590480 2025-12-18

RPL-EAP-001